Some Immune Characteristics of Interleukins and C –Reactive protein of cardiovascular disease patients in relation to blood groups
Immune Characteristics of Interleukins and C –Reactive protein of cardiovascular disease
DOI:
https://doi.org/10.63841/iue3261007Keywords:
Key word: Blood group, Interleukins, CRP, CDVAbstract
Blood groups are determined by the ABO antigen system and are significant for transfusion compatibility as well as vulnerability to specific systemic illnesses, including cardiovascular ailments. Dyslipidemia, pro-thrombotic factors, and inflammatory cytokines are more prevalent in people with blood types other than O. Their risk of developing atherosclerosis and CVD is increased by all of these factors. On the other hand, those with blood type O usually have better inflammatory and hemostatic profiles, which may offer some protection against cardiovascular disease (CVD). This research examines the relation between ABO blood group phenotypes and some important inflammatory biomarkers—interleukin-.6 (IL-6), interleukin-18 (IL-18), and C-reactive protein (CRP)—in patients with cardiovascular disease (CVD). A total of 80 individuals were engaged in a cross-sectional study, consisting of 50 CVD patients and 30 healthy controls. Blood groups were ascertained via tile agglutination, whereas serum concentrations of IL-6, IL-18, and CRP were quantified using ELISA and immunoturbidimetric techniques.
The results of CVD patients indicated IL-6 was highest in B+, and CRP was highest in O+, whereas IL-18 levels were variably distributed across groups but were usually Lower in non-O blood types. Participants with Group O+ actually had the highest IL-18 and CRP. These findings substantiate the hypothesis that non-O blood types have a greater susceptibility to systemic inflammation and cardiovascular problems.
ABO blood type profiling may serve as a valuable adjunct in assessing cardiovascular risk due to its simplicity and cost-effectiveness. The study emphasizes the need for further exploration of the immunogenetic mechanisms linking blood type antigens to inflammatory pathways, particularly across diverse populations such as the Kurdish demographic analyzed in this research.
Downloads
References
S.J. Ilstrup, "Blood Groups," Transfusion Medicine, 2021, pp. 135-167.
S.B. Abegaz, "Human ABO blood groups and their associations with different diseases," BioMed Research International, vol. 2021, no. 1, p. 6629060, 2021.
N. Quraishy and S. Sapatnekar, "Advances in blood typing," Advances in Clinical Chemistry, vol. 77, pp. 221-269, 2016.
D.R. Ewald and S.C. Sumner, "Blood type biochemistry and human disease," Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 8, no. 6, pp. 517-535, 2016.
S. Neshat, et al., "cardiovascular diseases risk predictors: ABO blood groups in a different role," Cardiology in Review, vol. 32, no. 2, pp. 174-179, 2024.
H.E. Groot, et al., "Genetically determined ABO blood group and its associations with health and disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, no. 3, pp. 830-838, 2020.
S.A. Moghadam, et al., "Association of ABO blood groups and Rh factor with periodontal disease prevalence in a population from Saravan, Iran," Zahedan Journal of Research in Medical Sciences, vol. 27, no. 1, 2021.
X. Jia, et al., "Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study," European Journal of Preventive Cardiology, vol. 30, no. 16, pp. 1731-1740, 2023.
A.S. Ayit, F.H.O.A. Khikani, and R.M. Abadi, "Prevalence of ABO blood group system in Southern Babylon, Iraq," Journal of Preventive, Diagnostic and Treatment Strategies in Medicine, vol. 1, no. 3, pp. 178-181, 2022.
V.R. Netala, et al., "Cardiovascular biomarkers: Tools for precision diagnosis and prognosis," International Journal of Molecular Sciences, vol. 26, no. 7, p. 3218, 2025.
G. Goodarzi, et al., "Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy," Molecular Biology Reports, vol. 48, no. 7, pp. 5443-5450, 2021.
I.G. Mukhtar and A.T. Abdullahi, "Relationship between ABO blood group phenotypes and some cardiovascular risk factors among undergraduate students in Kano, Nigeria," Nigerian Journal of Experimental and Clinical Biosciences, vol. 10, no. 4, pp. 116-123, 2022.
A.E. Altyar, et al., "Role of IL-2, IL-6, and TNF-α as potential biomarkers in ischemic heart disease: A comparative study of patients with CAD and non-CAD," Medical Sciences, vol. 13, no. 2, p. 40, 2025.
R. Zhao, et al., "Additive association of blood group A allele with 15 cardiometabolic diseases: A UK Biobank life-course study," Cardiovascular Diabetology, vol. 24, no. 1, p. 113, 2025.
M.S. Khan, et al., "Interleukin-6 and cardiovascular events in healthy adults: MESA," JACC: Advances, vol. 3, no. 8, p. 101063, 2024.
P.M. Ridker and M. Rane, "Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease," Circulation Research, vol. 128, no. 11, pp. 1728-1746, 2021.
N.N. Mehta, E. Degoma, and M.D. Shapiro, "IL-6 and cardiovascular risk: A narrative review," Current Atherosclerosis Reports, vol. 27, no. 1, p. 12, 2024.
Q. Chen, et al., "Identification of Acanthopanax trifoliatus (L.) Merr as a novel potential therapeutic agent against COVID-19 and pharyngitis," Molecules, vol. 30, no. 5, p. 1055, 2025.
C. Liu and C. Li, "C-reactive protein and cardiovascular diseases: A synthesis of studies based on different designs," European Journal of Preventive Cardiology, vol. 30, no. 15, pp. 1593-1596, 2023.
P. Egenolf, et al., "Impact of the blood group on postoperative CRP and leukocyte levels after primary total hip and knee arthroplasty," Technology and Health Care, vol. 32, no. 2, pp. 585-593, 2024.
R.N. Haile, "Do certain blood groups increase COVID-19 severity and mortality?" Global Epidemiology, p. 100212, 2025.
S. Stukas, et al., "ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients," PloS One, vol. 20, no. 4, p. e0320251, 2025.
M.A. Ortega, et al., "Recapping the features of SARS-CoV-2 and its main variants: Status and future paths," Journal of Personalized Medicine, vol. 12, no. 6, p. 995, 2022.
Z. Abbasi, et al., "Investigating how Interleukin-6 serum level, blood group type, and underlying diseases are associated in patients admitted to the COVID-19 intensive care unit: A retrospective study," The Open Public Health Journal, vol. 16, no. 1, 2023.
M. Mickelsson, et al., "ABO and RhD blood groups as contributors to dyslipidemia–a cross-sectional study," Lipids in Health and Disease, vol. 24, no. 1, p. 18, 2025.
W. Hafez, et al., "ABO blood group in relation to COVID-19 susceptibility and clinical outcomes: A retrospective observational study in the United Arab Emirates," Life, vol. 12, no. 8, p. 1157, 2022.
T. Eatz, et al., "Association of ABO blood type with infection and severity of COVID-19 in inpatient and longitudinal cohorts," COVID, vol. 3, no. 9, pp. 1429-1439, 2023.
M. Yaghooti-Khorasani, et al., "Evaluation of ABO blood group in subjects with CVD risk factors in a population sample from northeastern Iran," Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 14, no. 6, pp. 1689-1695, 2020.
H.-J. Lin, et al., "Breast cancer tumor microenvironment and molecular aberrations hijack tumoricidal immunity," Cancers, vol. 14, no. 2, p. 285, 2022.
Q. Shi, et al., "Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis," EClinicalMedicine, vol. 41, 2021.
R. Bawa, et al., Advances in Medical Biochemistry, Genomics, Physiology, and Pathology, Jenny Stanford Publishing, 2021.
A.T. Mohammadi, et al., Emerging Perspectives in Disease Pathogenesis and Management: Integrative Approaches in Understanding Complex Disorders, 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Academic Journal of International University of Erbil
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
